# OnCo record lantheus (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/lantheus/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "lantheus" ;
  schema:name "Lantheus"@en ;
  schema:alternateName "Progenics Pharmaceuticals, Inc."@en, "Progenics"@en, "Molecular Insight Pharmaceuticals, Inc."@en, "Molecular Insight Pharmaceuticals"@en ;
  schema:description "Lantheus makes Pylarify, the leading PSMA PET agent, with a new TruVu formulation approved in March 2026; in August 2026 it agreed to be bought by Curium, a deal not yet closed."@en ;
  schema:url <https://onco.cc/companies/lantheus/>, <https://www.lantheus.com> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.lantheus.com>, <https://www.sec.gov/Archives/edgar/data/1521036/000119312526331138/d167446d8k.htm>, <https://www.sec.gov/Archives/edgar/data/1521036/000119312526428324/d19181d8k.htm>, <https://www.sec.gov/Archives/edgar/data/1521036/000119312525162233/d89717d8k.htm> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/radiopharma/>, <https://onco.cc/fronts/imaging/> ;
  onco:drugs <https://onco.cc/drugs/pylarify/>, <https://onco.cc/drugs/i131-mibg/> ;
  onco:companies <https://onco.cc/companies/evergreen-theragnostics/>, <https://onco.cc/companies/curium/> ;
  onco:trials <https://onco.cc/trials/nct06298916/>, <https://onco.cc/trials/nct07357519/> .